Adhera Therapeutics, Inc. (ATRX)
OTCMKTS: ATRX · Delayed Price · USD
0.0075
+0.0008 (11.79%)
Apr 24, 2024, 2:51 PM EDT - Market closed
Company Description
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs.
The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes.
The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018.
Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.
Adhera Therapeutics, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Andrew Albert Kucharchuk M.B.A. |
Contact Details
Address: P.o. Box 2161 Wake Forest, North Carolina 27588 United States | |
| Phone | 919-578-5901 |
Stock Details
| Ticker Symbol | ATRX |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000737207 |
| CUSIP Number | 00687E109 |
| ISIN Number | US00687E4061 |
| Employer ID | 11-2658569 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andrew Albert Kucharchuk M.B.A. | Vice Chairman, Chief Operating Officer, Acting Chief Financial Officer and Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 18, 2024 | 8-K | Current Report |
| Jan 16, 2024 | 8-K | Current Report |
| Nov 29, 2023 | 8-K | Current Report |
| Nov 20, 2023 | 10-Q | Quarterly Report |
| Nov 15, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Oct 12, 2023 | 8-K | Current Report |
| Aug 21, 2023 | 10-Q | Quarterly Report |
| Aug 15, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Jun 29, 2023 | 8-K | Current Report |
| May 22, 2023 | 10-Q | Quarterly Report |